Results 71 to 80 of about 6,944 (246)

Rethinking control‐IQ+ technology: Simple strategies for easy optimization

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Control‐IQ+ is an automated insulin delivery (AID) algorithm approved for people with type 1 diabetes aged 2+ years and adults aged 18+ years with type 2 diabetes. While numerous publications support improved glycaemia and quality of life for people with diabetes, this practice paper is intended to encourage uptake for healthcare professionals
Viral N. Shah, Pratik Choudhary, Ilana Halperin, Ivana Rabbone, Dessi P. Zaharieva, Laurel Messer   +5 more
wiley   +1 more source

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials

Journal of Diabetes
Background The cardioprotective effects of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)‐based therapies in nondiabetic individuals with overweight or obesity remain underexplored.
Yue Yin, Minghan Zhang, Qiuyu Cao, Lin Lin, Jieli Lu, Yufang Bi, Yuhong Chen   +6 more
doaj   +1 more source

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials [PDF]

, 2020
Sushrima Gan, Adem Y. Dawed, Louise A. Donnelly, Anand Thakarakkattil Narayanan Nair, Colin N.A. Palmer, Viswanathan Mohan, Ewan R. Pearson   +6 more
openalex   +1 more source

Levodopa Efficacy and GLP‐1 Receptor Agonists

Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez, Christine Girges, Thomas Foltynie, Anne‐Marie Wills   +3 more
wiley   +1 more source

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract The clinical management of metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated steatohepatitis (MASH) is undergoing rapid evolution, driven by advances in noninvasive diagnostics and the recent approval of liver‐directed therapies.
Fernando Bril
wiley   +1 more source

Fixed ratio combinations GLP-1RA and basal insulin: literature review

Problems of Endocrinology
The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia’s risk.
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Ju. V. Gorbunova, E. V. Volotova, A. I. Robertus, I. E. Makarenko, V. B. Saparova, R. V. Drai, V. I. Petrov   +10 more
openaire   +2 more sources

Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes

Frontiers in Pharmacology
Background: Diabetes affects millions of people worldwide annually, and several methods, including medications, are used for its management; glucagon-like peptide-1 receptor agonists (GLP-1RAs) are one such class of medications.
Yongru Chen, Jingxian Chen, Jingxian Chen, Shuo Zhang, Shuo Zhang, Dan Zhu, Feiying Deng, Feiying Deng, Rui Zuo, Yufei Hu, Yue Zhao, Yale Duan, Benwei Lin, Fengwu Chen, Yun Liang, Jiaxiong Zheng, Barkat Ali Khan, Kaijian Hou   +17 more
doaj   +1 more source